SFPO and ESOP recommendations for the practical stability of anticancer drugs: An update.
(2013) Annales Pharmaceutiques Francaises — Vol. 71, n° 6, p. 376-389 (2013)
Files
SFPO--ESOP-Stability-2013.pdf
Restricted Access - Adobe PDF
- 978.72 KB
Details
- Authors
- Abstract
- The recommandations for the practical stability of anticancer drugs published in 2010 by the French Society of Hospital Pharmacists (SFPO) and the European Society of Oncology Pharmacists (ESOP) have been updated. Ten new molecules have been included (asparaginase, azacitidine, bevacizumab, clofarabine, eribuline mesylate, folinate sodium, levofolinate calcium, nelarabine, rituximab, temsirolimus).
- Affiliations
Citations
Vigneron, J., Astier, A., Trittler, R., Hecq, J.-D., Daouphars, M., Larsson, I., Pourroy, B., & Pinguet, F. (2013). SFPO and ESOP recommendations for the practical stability of anticancer drugs: An update. Annales Pharmaceutiques Francaises, 71(6), 376-389. https://doi.org/10.1016/j.pharma.2013.06.002 (Original work published 2013)